NO20016187L - Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister - Google Patents

Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister

Info

Publication number
NO20016187L
NO20016187L NO20016187A NO20016187A NO20016187L NO 20016187 L NO20016187 L NO 20016187L NO 20016187 A NO20016187 A NO 20016187A NO 20016187 A NO20016187 A NO 20016187A NO 20016187 L NO20016187 L NO 20016187L
Authority
NO
Norway
Prior art keywords
benzhydryl
azabicyclo
polymorphs
methoxybenzyl
oct
Prior art date
Application number
NO20016187A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016187D0 (no
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Michael Jon Gumkowski
David Joseph Muehlbauer
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20016187D0 publication Critical patent/NO20016187D0/no
Publication of NO20016187L publication Critical patent/NO20016187L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20016187A 1999-06-22 2001-12-18 Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister NO20016187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22
PCT/IB2000/000756 WO2000078759A1 (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016187D0 NO20016187D0 (no) 2001-12-18
NO20016187L true NO20016187L (no) 2001-12-18

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016187A NO20016187L (no) 1999-06-22 2001-12-18 Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister

Country Status (35)

Country Link
US (1) US6262067B1 (pt)
EP (1) EP1187834A1 (pt)
JP (1) JP2003502425A (pt)
KR (1) KR20020030280A (pt)
CN (1) CN1390216A (pt)
AP (1) AP2001002367A0 (pt)
AR (1) AR024411A1 (pt)
AU (1) AU767336B2 (pt)
BG (1) BG106205A (pt)
BR (1) BR0011835A (pt)
CA (1) CA2375265A1 (pt)
CO (1) CO5190663A1 (pt)
CZ (1) CZ20014458A3 (pt)
DZ (1) DZ3055A1 (pt)
EA (1) EA004264B1 (pt)
EC (1) ECSP003538A (pt)
EE (1) EE200100698A (pt)
HR (1) HRP20010920A2 (pt)
HU (1) HUP0201694A3 (pt)
IL (1) IL146410A0 (pt)
IS (1) IS6161A (pt)
MA (1) MA26744A1 (pt)
MX (1) MXPA02000033A (pt)
NO (1) NO20016187L (pt)
NZ (1) NZ515348A (pt)
OA (1) OA11952A (pt)
PA (1) PA8496701A1 (pt)
PE (1) PE20010322A1 (pt)
PL (1) PL352899A1 (pt)
SK (1) SK18672001A3 (pt)
TN (1) TNSN00137A1 (pt)
TR (1) TR200103688T2 (pt)
UY (1) UY26211A1 (pt)
WO (1) WO2000078759A1 (pt)
ZA (1) ZA200110387B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
JP2006503859A (ja) * 2002-10-04 2006-02-02 メルク シャープ エンド ドーム リミテッド 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体
AR042444A1 (es) 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
EP1781624A4 (en) * 2004-07-02 2010-06-23 Taro Pharma Ind PROCESS FOR THE PREPARATION OF 1-METHOXYMETHYL-5,5-DIPHENYLBARBITURIC ACID
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
RU2103269C1 (ru) * 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
ZA200110387B (en) 2002-12-19
UY26211A1 (es) 2001-01-31
TNSN00137A1 (fr) 2002-05-30
BR0011835A (pt) 2002-03-05
DZ3055A1 (fr) 2004-03-27
NZ515348A (en) 2003-07-25
IS6161A (is) 2001-11-13
EA004264B1 (ru) 2004-02-26
OA11952A (en) 2006-04-13
NO20016187D0 (no) 2001-12-18
EP1187834A1 (en) 2002-03-20
BG106205A (bg) 2002-07-31
MXPA02000033A (es) 2002-07-02
AU4774500A (en) 2001-01-09
SK18672001A3 (sk) 2002-08-06
AP2001002367A0 (en) 2001-12-31
PA8496701A1 (es) 2002-07-30
JP2003502425A (ja) 2003-01-21
KR20020030280A (ko) 2002-04-24
EE200100698A (et) 2003-02-17
EA200101179A1 (ru) 2002-06-27
AU767336B2 (en) 2003-11-06
MA26744A1 (fr) 2004-12-20
CN1390216A (zh) 2003-01-08
HUP0201694A2 (en) 2002-09-28
ECSP003538A (es) 2002-01-25
HUP0201694A3 (en) 2002-10-28
US6262067B1 (en) 2001-07-17
CZ20014458A3 (cs) 2002-03-13
PL352899A1 (en) 2003-09-22
AR024411A1 (es) 2002-10-02
CA2375265A1 (en) 2000-12-28
HRP20010920A2 (en) 2003-02-28
IL146410A0 (en) 2002-07-25
WO2000078759A1 (en) 2000-12-28
PE20010322A1 (es) 2001-03-14
TR200103688T2 (tr) 2002-12-23
CO5190663A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
EE05019B1 (et) Kristalsete orgaaniliste hendite stabiilsed kindla kujuga osakesed
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO20004261D0 (no) 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister
NO20016187D0 (no) Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister
NO20002036L (no) Cyklopentenderivater anvendbare som antagonister for motilinreseptoren
NZ513732A (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
NO20014356L (no) Bifenylderivater som antagonister av neurokinin-1 reseptoren
NO994106D0 (no) Oksazolidiner som 5-HT2A-antagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO20006227D0 (no) Tetrahydroquiolinderivater som glycin antagonister
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO20015845L (no) Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister
AU1735200A (en) Novel isoxazoline fibrinogen receptor antagonists
NO995782L (no) Kvarternaere ammoniumforbindelser som tachykinin-antagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
FI943359A (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
FI943872A0 (fi) 2,6-metano-2H-kinditsiinijohdannainen 5-HT3-reseptoriantagonistina
DK0882044T3 (da) 1,4-dihydropyridinforbindelser som bradykinin-antagonister
DK1207159T3 (da) Heteroaromatiske derivater som dopamin-D4-receptorantagonister
DK0994876T3 (da) Kvaternære ammoniumforbindelser som tachykinin-antagonister
AU2002334100A1 (en) Azabicyclic amine derivatives as nk-1 receptor antagonists
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik
DK1077942T3 (da) Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application